No Data
[Popular Industry] The Global competition accelerates as China's Innovative Drugs Industry enters a new cycle.
King Wu Finance | The Global Innovative Drugs research and development landscape is undergoing profound changes. The latest assessment by McKinsey shows that the USA dominates the leading tier of global drug development, accounting for over half of the world's new drug research, while China's new drug development has entered the forefront of the global second tier. In the most advanced fields of stem cell therapy and gene therapy, the number of clinical studies being conducted puts China and the USA in the top two positions globally. The equal number of clinical studies between China and the USA marks the transition of Chinese innovative drugs from "catching up" to "keeping pace with" and even "leading". In this process, the frequent clinical achievements of domestic enterprises and enhanced policy support are propelling the Industry into a rapid development phase.
Chinese Biopharma Firms Chase Hong Kong IPO, After Duality's Sizzling Debut
Hong Kong stock movement | InnoCare Pharma-B (09606) rose over 16% to a new high. The company focuses on the development of ADC new drugs, and its core products initially demonstrate therapeutic potential.
Ying'en Biological-B (09606) rose more than 16% in the morning, peaking at HKD 232.8, setting a new high since listing. As of the time of writing, it has risen by 13.2%, trading at HKD 226.4, with a transaction volume of HKD 0.175 billion.
Guotai Junan: Initiates a "Shareholding" rating for Yingsheng Biotechnology-B (09606) with a Target Price of 300.70 HKD.
The company focuses on the research and development of new ADC drugs, achieving multiple License-out external authorizations for its products. DB-1303 and DB-1311 have shown preliminary therapeutic potential, with a broad market space.
On the first day, it surged 117%! ADC star company InnoCare Biotech-B (09606) listed on the Hong Kong Stock Exchange, setting a record for the highest increase in new stocks this year.
On April 15, antibody-drug conjugate (ADC) star company Igenbio-B (09606) was officially listed on the Main Board of the Hong Kong Stock Exchange.
Hong Kong Stocks Rise Slightly; Duality Biotherapeutics Soars 117% in Debut
